BioSpace News Archive

Vivoryon Therapeutics N.V. announced the presentation of preclinical data on the Company’s N3pE amyloid-targeting molecules at the prestigious Alzheimer’s Association International Conference in San Diego.

The Alzheimer’s Association® will present seven awards at the Alzheimer’s Association International Conference® 2022, recognizing researchers for their varied expertise, noteworthy achievements and innovative contributions to the field of Alzheimer’s and dementia science.

Anavex Life Sciences Corp. announced the first entire clinical gene pathway data from the ANAVEX®2-73-PDD-001 Parkinson’s Disease Dementia study at the Alzheimer’s Association International Conference, taking place in San Diego, CA and virtually on July 31 – August 4, 2022.

Alzheimer’s disease blood biomarkers may revolutionize the diagnosis of Alzheimer’s in the future, but are not yet ready for widespread use, according to a newly-published article by leading international clinicians and researchers convened by the Alzheimer’s Association®.

Innovent Biologics, Inc. and Laekna Therapeutics jointly announced that the first patient has been dosed in a Phase 1/2 clinical trial of a three-drug combination therapy in patients with specific solid tumors who were resistant to anti-PD-1/PD-L1 therapy at the West China Second Hospital of Sichuan University.

New insights into factors that may predict, increase or protect against the impact of COVID-19 and the pandemic on memory and thinking skills were revealed by multiple studies reported at the Alzheimer’s Association International Conference® 2022 in San Diego and virtually.

Zenas BioPharma announced that it has received approval of its Investigational New Drug application from the National Medical Products Administration of China for the initiation of a Phase 1/2 clinical study of ZB001 for the treatment of Thyroid Eye Disease.

Data released from C2N Diagnostics, presented at the Alzheimer’s Association International Conference, demonstrated that a blood test combining the Aβ42/40 ratio, a component of C2N’s commercially available PrecivityADTM blood test, with a unique p-tau217 ratio leads to testing performance that points to accuracy comparable to more complex amyloid PET imaging and invasive cerebrospinal fluid tests in identifying Alzheimer’s brain pathology.

Vivoryon Therapeutics N.V., a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, announced detailed results of the completed parallel group, dose-finding part of its European Phase 2b study VIVIAD.

SyneuRx™ International, a global biotech company focused on the development of new classes of drugs for COVID-19 and multiple major central nervous system disorders, announced results from its phase 2 clinical trial evaluating the efficacy and safety of SNB01, a novel COVID-19 oral antiviral candidate.